Fenofibrate IR Pellets are pharmaceutical-grade immediate-release multiparticulate pellets developed for oral formulation applications requiring rapid release of Fenofibrate from individual pellet units. The multiparticulate format provides formulation flexibility by allowing control over active loading, pellet size, physical characteristics, content uniformity and dissolution performance.
Fenofibrate is a well-characterized pharmaceutical active ingredient with CAS Number 49562-28-9, molecular formula C₂₀H₂₁ClO₄, and molecular weight 360.83 g/mol. Fenofibrate is a crystalline compound with limited aqueous solubility, making formulation design and appropriate particle characteristics important considerations during development. For this reason, Fenofibrate pellet technology can provide a practical platform for developing consistent oral multiparticulate formulations.
Fenofibrate IR Pellets are formulated as individual multiparticulate units in which Fenofibrate is distributed throughout or associated with the pellet structure. Unlike a conventional single-unit dosage form, a multiparticulate system contains numerous individual pellet units, allowing formulation developers to manage the physical and performance characteristics of the overall formulation.
The performance of Fenofibrate Immediate-Release Pellets depends on several formulation and manufacturing variables, including active ingredient loading, pellet size, pellet composition, porosity, surface characteristics, excipient selection and manufacturing conditions. These factors can influence the rate at which the active ingredient becomes available from the pellet system.
A well-controlled pellet system can provide consistent particle characteristics and support reproducible processing during capsule filling or other oral formulation operations.
Fenofibrate 66% IR Pellets represent a commercially documented high-loading pellet format. Commercial pharmaceutical pellet portfolios report Fenofibrate pellet strengths around the 60–66% range, including 66% w/w formats.
For an SDP product page, the 66% w/w strength should be stated as an available product strength only when it corresponds to the current SDP product specification and COA.
The active loading of a pellet is an important formulation parameter because it determines the quantity of Fenofibrate present within a defined pellet mass. Higher loading can also influence pellet composition, physical properties and manufacturing requirements.
The multiparticulate structure of Fenofibrate IR Pellets provides flexibility for oral formulation development. Each pellet acts as an individual unit, while the complete formulation contains a population of pellets with controlled physical and chemical characteristics.
This format can be considered for applications such as:
The final suitability of the pellets depends on the intended formulation, manufacturing process and applicable finished-product requirements.
One important application of pharmaceutical pellets is capsule filling. Fenofibrate IR Pellets can be designed with suitable particle-size distribution and flow characteristics to support capsule-filling processes.
Particle size, bulk density, tapped density, flow behavior, friability and pellet morphology can all influence the handling characteristics of a pellet system. Consistent pellet characteristics are therefore important for achieving uniform filling and reproducible formulation performance.
For commercial production, the appropriate pellet specification should be established according to the intended capsule formulation and manufacturing process.
The immediate-release behavior of Fenofibrate pellets is influenced by the composition and structure of the pellet system. Important factors can include:
Because these factors can vary between formulations, the dissolution profile of Fenofibrate IR Pellets should be established through the applicable validated finished-product method.
A specific universal dissolution value should not be assigned to all Fenofibrate pellet products because acceptance criteria can vary according to formulation design and product specification.
Active loading is one of the most important characteristics of a pharmaceutical pellet system. The intended Fenofibrate concentration must be consistently maintained throughout the manufactured pellet batch.
Content uniformity is particularly important for multiparticulate systems because the active ingredient should be distributed consistently among the pellet population. Appropriate manufacturing controls and analytical testing help evaluate the uniformity of Fenofibrate within the finished product.
The finished-pellet assay should always be evaluated against the applicable product specification. The assay specification for Fenofibrate API should not automatically be applied to the finished pellet.
High-quality Fenofibrate Pharmaceutical Pellets can be evaluated through a combination of chemical, physical and performance parameters.
Chemical quality evaluation may include identification, HPLC assay, active loading and related-substance testing.
Physical evaluation can include:
Performance evaluation may include:
Together, these characteristics help establish the suitability of the pellets for the intended pharmaceutical formulation.
Fenofibrate pellet technology provides formulation developers with a flexible multiparticulate platform. The pellet system can be optimized according to the desired active loading, particle-size range, physical characteristics and release requirements.
During formulation development, parameters such as pellet composition, active loading, particle size and manufacturing conditions can be evaluated to achieve consistent finished-product performance.
For manufacturers developing oral multiparticulate formulations, the use of standardized pellet characteristics can also simplify downstream processing and capsule-filling operations.
Fenofibrate IR Pellets from Swapnroop are positioned as pharmaceutical-grade multiparticulate pellets for formulation and bulk pharmaceutical applications.
Key advantages include:
Fenofibrate IR Pellets Manufacturer in India solutions can support several pharmaceutical formulation requirements, including oral multiparticulate development, capsule filling and immediate-release formulation research.
The principal application areas include:
Fenofibrate pellets can be incorporated into oral formulations where individual pellet units are preferred.
Controlled pellet size and physical characteristics can support capsule-filling operations.
The pellet system can be evaluated and optimized for immediate-release dissolution performance.
Fenofibrate pellets can support formulation development, process optimization and scale-up activities.
Pellet products can be supplied according to defined active loading, pellet characteristics, batch quantity and packaging requirements.
Quality control of Fenofibrate IR Pellets involves multiple stages of evaluation.
Fenofibrate identification can be performed using an appropriate validated analytical method such as HPLC, IR or another suitable procedure.
The finished pellet assay is determined using an appropriate validated analytical method according to the applicable product specification.
The Fenofibrate concentration is evaluated to confirm that the finished pellets meet the specified active loading.
Loss on drying and/or water content may be evaluated according to the applicable product specification.
Physical characteristics can include particle size, bulk density, tapped density, friability, sphericity and pellet morphology.
Content uniformity testing helps assess consistent distribution of Fenofibrate within the finished multiparticulate system.
Immediate-release dissolution testing is performed using the validated finished-product method and applicable acceptance criteria.
As a Fenofibrate IR Pellets Manufacturer and Supplier in India, Swapnroop can present Fenofibrate pellet solutions for pharmaceutical formulation requirements, subject to the applicable product specification.
The product can be positioned for customers looking for:
Fenofibrate IR Pellets Manufacturer in India, Fenofibrate IR Pellets Supplier in India, Fenofibrate 66% Pellets, Fenofibrate Pharmaceutical Pellets, Fenofibrate Immediate-Release Pellets, Fenofibrate Multiparticulate Pellets, and Fenofibrate Pellets for Capsule Filling.
The final active loading, pellet size, physical characteristics and performance specifications should be confirmed against the applicable product specification before commercial use.
Fenofibrate IR Pellets can be supplied in suitable pharmaceutical packaging according to the required batch quantity, active loading, pellet characteristics and customer requirements.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| Water Content | NMT 1.0% |